DEFINING SIGNALING PATHWAYS AND EFFECTIVE COMBINATION THERAPY TO IMPROVE OUTCOMES FOR PATIENTS WITH FGFR2-DRIVEN BILIARY CANCER

$840,000FY2022Department of the ArmyDOD

The General Hospital Corporation

Investigators